Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Lancet Rheumatol. 2023 Mar 27;5(5):e274–e283. doi: 10.1016/s2665-9913(23)00064-4

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Cumulative incidence curves for outcomes after immune checkpoint inhibitor initiation for cancer treatment for pre-existing rheumatoid arthritis (RA) cases (n=87) and matched non-RA comparators (n=203). A. All-cause mortality. B. All-grade irAE. C. Grade 3+ irAE. D. All-grade irAE, excluding RA flare for cases and inflammatory arthritis for matched comparators. E. Grade 3+ irAE, excluding RA flare for cases and inflammatory arthritis for matched comparators.